Ceftriaxone Sodium

Ceftriaxone sodium is a broad-spectrum third-generation cephalosporin with a low MIC, very stable to beta-lactamase, widely distributed in body fluids and various organs, with few side effects and good stability. It has strong antibacterial activity against Enterobacteriaceae, and both influenza bacilli and gonococci that produce and do not produce beta-lactamase are highly sensitive to this product. It has stronger antibacterial effects on Escherichia coli, aerogenes, various Proteus species and influenza bacilli than second-generation cephalosporins. It has stronger activity against gram-positive cocci such as hemolytic streptococci and pneumococci.

The main component of this product is cefotaxime sodium, and its chemical name is (6R, 7R)-3-[(acetyloxy)methyl]-7-[(2-amino-4-thiazolyl)-(methoxyimino)acetylamino]-8-oxo-5-thia-1-azacyclo[4,2,0]oct-2-ene-2-carboxylate sodium. The molecular formula is C16H16N5NaO7S2, and the molecular weight is 477.45.

It is suitable for respiratory tract infections, urinary tract infections, gastrointestinal infections, meningitis, sepsis, soft tissue infections, ENT infections, reproductive tract infections, orthopedic infections, etc. caused by sensitive bacteria. Ceftriaxone sodium can be used as the first choice drug for meningitis, especially meningitis in infants and young children.

Intramuscular or intravenous injection, adults, moderate infection, 1g/time, 1 time/12 hours; severe infection, more serious drug allergy, more serious drug allergy, 8g~12g/day, divided into 3~4 times; children 100mg~150mg/kg per day, divided into 2~4 times; newborns 50mg/kg per day, divided into 2~4 times. This product can also be used for intravenous drip, preferably 1g~2g dissolved in normal saline or glucose injection solution for dilution, and the drip is completed within 20~60 minutes.

The incidence of side effects is low, about 3-5%, rash and drug fever are about 2-5%, phlebitis, diarrhea, nausea, vomiting, loss of appetite and other digestive tract reactions are seen in 1% of patients, alkaline phosphatase or serum transaminase slightly elevated in about 3%, temporary blood urea nitrogen and creatinine increased in 0.7% and 0.3% respectively, leukopenia, acidosis or thrombocytopenia are rare. Occasionally headache, numbness, dyspnea and facial flushing occur. After using this product, 0.28% of patients may develop mucosal candidiasis.

It is contraindicated in patients who are allergic to cephalosporins.

1. It has a synergistic effect with gentamicin or tobramycin against Pseudomonas aeruginosa; it has a synergistic effect with amikacin against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. 2. When used in combination with aminoglycoside antibiotics, renal function should be followed up during medication. 3. When large doses of cefotaxime are used in combination with strong diuretics, attention should be paid to changes in renal function. 4. Cefotaxime can be diluted with sodium chloride injection or glucose solution, but cannot be mixed with sodium bicarbonate solution. 5. When used in combination with azlocillin or mezlocillin, the total clearance rate of this product can be reduced. If the two are used in combination, the dose should be appropriately reduced.

Keep tightly closed in a cool, dark and dry place.

Suzhou Wanqing Pharmaceutical Co., Ltd.

• Founded in:

  2003-03-10

• Address:

  Room 625-53, 6th Floor, East Building, Incubation Building, No. 6, Beijing West Road, Taicang, Suzhou

• Tax NO.:

  913205857473146062

• Registered Funds:

  2 million yuan

• Email:

  Log in to view